This article is provided for educational and research purposes only. Cagrilintide and all peptides discussed herein are intended solely for in vitro laboratory investigation and are not approved for human or animal use.
Introduction: Amylin Signaling as a Pharmacological Target
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid neuroendocrine hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Its physiological actions—delayed gastric emptying, suppression of postprandial glucagon secretion, and promotion of satiety via hindbrain circuits—have made the amylin receptor system a compelling target for metabolic research. However, native amylin is rapidly cleared from circulation (plasma half-life ~13 minutes) and is prone to fibrillar aggregation. Cagrilintide (AM833/NN9838) is a long-acting acylated amylin analogue engineered to overcome these limitations, achieving a half-life of 159–195 hours through lipidation-mediated albumin binding (Kruse et al., 2021). This review examines cagrilintide’s receptor pharmacology, focusing on amylin receptor subtype selectivity, RAMP protein interactions, receptor trafficking, and the structural basis of dual agonism at calcitonin-family receptors.
The amylin receptor family comprises three heterodimeric complexes formed by the calcitonin receptor (CTR), a class B1 GPCR, in association with one of three receptor activity-modifying proteins. These obligate heterodimers—AMY1R (CTR+RAMP1), AMY2R (CTR+RAMP2), and AMY3R (CTR+RAMP3)—were first characterized by Christopoulos et al. (1999) and represent pharmacologically distinct entities with unique ligand selectivity profiles.
RAMP Protein Structure and Function
RAMPs are single-pass transmembrane glycoproteins of 148–174 amino acids, sharing approximately 30% sequence identity while maintaining a conserved architecture: a large extracellular domain with four disulfide-bonded cysteines, a single transmembrane helix, and a short intracellular tail. RAMP association with CTR produces several critical pharmacological consequences:
Enhanced amylin affinity: RAMP1 and RAMP3 co-expression induces a 20- to 30-fold increase in amylin potency for cAMP accumulation relative to CTR alone (Lee et al., 2016).
Altered ligand selectivity: AMY1R binds salmon calcitonin, amylin, and CGRP with comparable affinity, whereas AMY2R and AMY3R preferentially bind amylin and sCT over CGRP.
Receptor trafficking modulation: RAMP3 contains a PDZ domain that interacts with N-ethylmaleimide-sensitive factor, redirecting internalized receptor complexes toward recycling rather than lysosomal degradation (Pham et al., 2019).
Allosteric signal propagation: RAMP3 allosterically alters CTR extracellular loop 2 conformation, producing peptide-specific signaling across cAMP and ERK phosphorylation pathways (Pham et al., 2019).
All compounds referenced in this article are sold strictly for research purposes only and are not intended for human consumption or any form of self-administration.
Cagrilintide: Molecular Design and Receptor Binding Profile
Cagrilintide is derived from the human amylin backbone with lipidation at lysine position 1 using a C18 fatty diacid linker, enabling reversible albumin binding analogous to the strategy employed in GLP1-S (GLP1-S). Additional substitutions reduce amyloidogenic propensity while preserving receptor engagement.
In Vitro Binding Affinity
Competitive radioligand binding assays established Ki values of 3.5 nM at AMY3R and 6.8 nM at CTR, confirming nanomolar-range binding across all four receptor targets (Kruse et al., 2021). Cagrilintide functions as a non-selective agonist of CTR and all three AMYRs, activating Gs-mediated cAMP accumulation with comparable potency across subtypes (Cao et al., 2025). This non-selective profile distinguishes it from newer analogues: NN1213 achieves ~29-fold selectivity for AMY3R over CTR (Dahl et al., 2024), while eloralintide (LY3841136) demonstrates an AMYR-preferring profile (Briere et al., 2025).
Cao et al. (2025) resolved cryo-EM structures of cagrilintide bound to Gs-coupled active-state complexes of AMY1R, AMY2R, AMY3R, and CTR. These structures revealed an amylin-like bypass binding mode at AMYRs, where the peptide’s N-terminal segment threads through the receptor extracellular domain. At CTR, cagrilintide introduces a distinctive intra-peptide ionic lock stabilizing a predominant bypass conformation not observed with other calcitonin-family peptides. Molecular dynamics simulations revealed receptor-specific differences in TM6 displacement, ECD flexibility, and RAMP interface contacts—dynamic signatures hypothesized to underlie cagrilintide’s unique signaling profile.
Receptor Trafficking and Subunit Dynamics
Following agonist binding, AMYRs undergo GRK-mediated phosphorylation, beta-arrestin recruitment, and clathrin-dependent internalization. Cagrilintide exhibits a receptor residence time of 3–6 minutes across all AMYR subtypes (Cao et al., 2025), suggesting that its protracted in vivo activity derives primarily from the albumin depot mechanism rather than sustained receptor occupancy.
Gostynska et al. (2024) demonstrated that AMY3R exhibits substantially greater thermostability (Tm ~39°C) compared to AMY1R and AMY2R (~29°C), resulting in different baseline distributions of heteromeric versus free CTR populations. Amylin and alpha-CGRP promote CTR–RAMP1/2 association, while calcitonin promotes dissociation at AMY3R—revealing that observed cAMP responses represent composite contributions from both heteromeric receptors and free CTR subunits.
Central Nervous System Signaling
The satiogenic effects of amylin receptor agonists are mediated through receptors in the area postrema (AP), a circumventricular organ outside the blood-brain barrier. AP neurons project to the nucleus tractus solitarius (NTS) and lateral parabrachial nucleus (LPBN), establishing a relay circuit modulating both homeostatic and hedonic feeding pathways (Hankir & Le Foll, 2025). Carvas et al. (2025) demonstrated using knockout models that cagrilintide’s effects depend specifically on AMY1R and AMY3R, with genetic ablation substantially attenuating efficacy.
The rationale for combining cagrilintide with GLP-1 receptor agonists rests on non-overlapping receptor targets. GLP-1 receptors concentrate in the hypothalamic arcuate nucleus, while amylin receptors predominate in the hindbrain AP-NTS circuit. The REDEFINE 1 trial (Garvey et al., 2025) demonstrated that co-administration produced 22.7% mean body weight reduction at 68 weeks, exceeding either agent alone and prompting investigation of combinations with other compounds including GLP2-T (GLP2-T) and GLP3-R (GLP3-R).
Disclaimer: All peptides discussed are intended for laboratory research only. They are not for human or animal use and should not be used for self-medication or any clinical application.
What receptor subtypes does cagrilintide activate?
Cagrilintide is a non-selective agonist of CTR and all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R), with Ki values of 3.5 nM at AMY3R and 6.8 nM at CTR (Kruse et al., 2021).
How do RAMP proteins determine amylin receptor pharmacology?
RAMP1–3 heterodimerize with CTR to form pharmacologically distinct amylin receptor subtypes, altering ligand selectivity, G protein coupling efficiency, cell-surface expression, and post-endocytic trafficking fate.
What structural features distinguish cagrilintide binding at CTR versus AMYRs?
Cryo-EM structures reveal an amylin-like bypass binding mode at AMYRs but a unique intra-peptide ionic lock at CTR. Molecular dynamics indicate receptor-specific differences in TM6 displacement and ECD flexibility (Cao et al., 2025).
Which brain regions mediate cagrilintide’s effects on energy balance?
Cagrilintide activates receptors in the area postrema, with signals relayed through the NTS and LPBN to forebrain structures including the central amygdala, modulating homeostatic and hedonic feeding circuits (Hankir & Le Foll, 2025; Carvas et al., 2025).
How does cagrilintide achieve its long half-life?
A C18 fatty diacid moiety at the N-terminal lysine enables reversible albumin binding, protecting against renal clearance and enzymatic degradation to achieve a half-life of 159–195 hours (Kruse et al., 2021).
What distinguishes cagrilintide from newer AMYR-selective analogues?
Cagrilintide is non-selective across CTR and AMYRs, while NN1213 achieves ~29-fold AMY3R selectivity over CTR and eloralintide demonstrates an AMYR-preferring profile, potentially producing distinct biased signaling patterns (Dahl et al., 2024; Briere et al., 2025).
How do amylin and GLP-1 receptor agonists produce complementary effects?
Amylin receptors in the hindbrain and GLP-1 receptors in the hypothalamus enable parallel modulation of distinct satiety pathways. REDEFINE 1 showed 22.7% mean weight reduction with the combination at 68 weeks (Garvey et al., 2025).
References
Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. PubMed
Cao J, Belousoff MJ, Johnson RM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun. 2025;16:3389. PubMed
Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine. 2025;118:105836. PubMed
Gostynska SE, Karim JA, Ford BE, et al. Amylin receptor subunit interactions are modulated by agonists and determine signaling. Sci Signal. 2024;17(859):eadt8127. PubMed
Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235-242. PubMed
Lee SM, Hay DL, Pioszak AA. Calcitonin and Amylin Receptor Peptide Interaction Mechanisms. J Biol Chem. 2016;291(16):8686-8700. PubMed
Pham V, Zhu Y, Dal Maso E, et al. Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor. ACS Pharmacol Transl Sci. 2019;2(3):183-197. PubMed
Dahl K, Raun K, Hansen JL, et al. NN1213 – A Potent, Long-Acting, and Selective Analog of Human Amylin. J Med Chem. 2024;67(14):11688-11700. PubMed
Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity. Mol Metab. 2025;102:102271. PubMed
Hankir MK, Le Foll C. Central nervous system pathways targeted by amylin in the regulation of food intake. Biochimie. 2025;229:95-104. PubMed
Volcansek S, Koceva A, Jensterle M, et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Ther. 2025;16(6):1207-1227. PubMed
D’Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90. PubMed
Garvey WT, Bluher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and GLP1-S in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. PubMed
Discover how BPC-157 benefits are setting a new standard for gut healing peptides, offering impressive potential for gastrointestinal recovery where traditional NSAIDs often fall short. If you’re curious about innovative, science-backed approaches to gut health, this might be the breakthrough you’ve been waiting for.
Cagrilintide and Amylin Receptor Pharmacology: Dual Agonism, RAMP Interactions, and Receptor Trafficking
This article is provided for educational and research purposes only. Cagrilintide and all peptides discussed herein are intended solely for in vitro laboratory investigation and are not approved for human or animal use.
Introduction: Amylin Signaling as a Pharmacological Target
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid neuroendocrine hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Its physiological actions—delayed gastric emptying, suppression of postprandial glucagon secretion, and promotion of satiety via hindbrain circuits—have made the amylin receptor system a compelling target for metabolic research. However, native amylin is rapidly cleared from circulation (plasma half-life ~13 minutes) and is prone to fibrillar aggregation. Cagrilintide (AM833/NN9838) is a long-acting acylated amylin analogue engineered to overcome these limitations, achieving a half-life of 159–195 hours through lipidation-mediated albumin binding (Kruse et al., 2021). This review examines cagrilintide’s receptor pharmacology, focusing on amylin receptor subtype selectivity, RAMP protein interactions, receptor trafficking, and the structural basis of dual agonism at calcitonin-family receptors.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Amylin Receptor Architecture: CTR–RAMP Heterodimers
The amylin receptor family comprises three heterodimeric complexes formed by the calcitonin receptor (CTR), a class B1 GPCR, in association with one of three receptor activity-modifying proteins. These obligate heterodimers—AMY1R (CTR+RAMP1), AMY2R (CTR+RAMP2), and AMY3R (CTR+RAMP3)—were first characterized by Christopoulos et al. (1999) and represent pharmacologically distinct entities with unique ligand selectivity profiles.
RAMP Protein Structure and Function
RAMPs are single-pass transmembrane glycoproteins of 148–174 amino acids, sharing approximately 30% sequence identity while maintaining a conserved architecture: a large extracellular domain with four disulfide-bonded cysteines, a single transmembrane helix, and a short intracellular tail. RAMP association with CTR produces several critical pharmacological consequences:
All compounds referenced in this article are sold strictly for research purposes only and are not intended for human consumption or any form of self-administration.
Cagrilintide: Molecular Design and Receptor Binding Profile
Cagrilintide is derived from the human amylin backbone with lipidation at lysine position 1 using a C18 fatty diacid linker, enabling reversible albumin binding analogous to the strategy employed in GLP1-S (GLP1-S). Additional substitutions reduce amyloidogenic propensity while preserving receptor engagement.
In Vitro Binding Affinity
Competitive radioligand binding assays established Ki values of 3.5 nM at AMY3R and 6.8 nM at CTR, confirming nanomolar-range binding across all four receptor targets (Kruse et al., 2021). Cagrilintide functions as a non-selective agonist of CTR and all three AMYRs, activating Gs-mediated cAMP accumulation with comparable potency across subtypes (Cao et al., 2025). This non-selective profile distinguishes it from newer analogues: NN1213 achieves ~29-fold selectivity for AMY3R over CTR (Dahl et al., 2024), while eloralintide (LY3841136) demonstrates an AMYR-preferring profile (Briere et al., 2025).
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Cryo-EM Structural Insights
Cao et al. (2025) resolved cryo-EM structures of cagrilintide bound to Gs-coupled active-state complexes of AMY1R, AMY2R, AMY3R, and CTR. These structures revealed an amylin-like bypass binding mode at AMYRs, where the peptide’s N-terminal segment threads through the receptor extracellular domain. At CTR, cagrilintide introduces a distinctive intra-peptide ionic lock stabilizing a predominant bypass conformation not observed with other calcitonin-family peptides. Molecular dynamics simulations revealed receptor-specific differences in TM6 displacement, ECD flexibility, and RAMP interface contacts—dynamic signatures hypothesized to underlie cagrilintide’s unique signaling profile.
Receptor Trafficking and Subunit Dynamics
Following agonist binding, AMYRs undergo GRK-mediated phosphorylation, beta-arrestin recruitment, and clathrin-dependent internalization. Cagrilintide exhibits a receptor residence time of 3–6 minutes across all AMYR subtypes (Cao et al., 2025), suggesting that its protracted in vivo activity derives primarily from the albumin depot mechanism rather than sustained receptor occupancy.
Gostynska et al. (2024) demonstrated that AMY3R exhibits substantially greater thermostability (Tm ~39°C) compared to AMY1R and AMY2R (~29°C), resulting in different baseline distributions of heteromeric versus free CTR populations. Amylin and alpha-CGRP promote CTR–RAMP1/2 association, while calcitonin promotes dissociation at AMY3R—revealing that observed cAMP responses represent composite contributions from both heteromeric receptors and free CTR subunits.
Central Nervous System Signaling
The satiogenic effects of amylin receptor agonists are mediated through receptors in the area postrema (AP), a circumventricular organ outside the blood-brain barrier. AP neurons project to the nucleus tractus solitarius (NTS) and lateral parabrachial nucleus (LPBN), establishing a relay circuit modulating both homeostatic and hedonic feeding pathways (Hankir & Le Foll, 2025). Carvas et al. (2025) demonstrated using knockout models that cagrilintide’s effects depend specifically on AMY1R and AMY3R, with genetic ablation substantially attenuating efficacy.
Dual Pathway Engagement: Amylin–GLP-1 Complementarity
The rationale for combining cagrilintide with GLP-1 receptor agonists rests on non-overlapping receptor targets. GLP-1 receptors concentrate in the hypothalamic arcuate nucleus, while amylin receptors predominate in the hindbrain AP-NTS circuit. The REDEFINE 1 trial (Garvey et al., 2025) demonstrated that co-administration produced 22.7% mean body weight reduction at 68 weeks, exceeding either agent alone and prompting investigation of combinations with other compounds including GLP2-T (GLP2-T) and GLP3-R (GLP3-R).
Disclaimer: All peptides discussed are intended for laboratory research only. They are not for human or animal use and should not be used for self-medication or any clinical application.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Frequently Asked Questions
What receptor subtypes does cagrilintide activate?
Cagrilintide is a non-selective agonist of CTR and all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R), with Ki values of 3.5 nM at AMY3R and 6.8 nM at CTR (Kruse et al., 2021).
How do RAMP proteins determine amylin receptor pharmacology?
RAMP1–3 heterodimerize with CTR to form pharmacologically distinct amylin receptor subtypes, altering ligand selectivity, G protein coupling efficiency, cell-surface expression, and post-endocytic trafficking fate.
What structural features distinguish cagrilintide binding at CTR versus AMYRs?
Cryo-EM structures reveal an amylin-like bypass binding mode at AMYRs but a unique intra-peptide ionic lock at CTR. Molecular dynamics indicate receptor-specific differences in TM6 displacement and ECD flexibility (Cao et al., 2025).
Which brain regions mediate cagrilintide’s effects on energy balance?
Cagrilintide activates receptors in the area postrema, with signals relayed through the NTS and LPBN to forebrain structures including the central amygdala, modulating homeostatic and hedonic feeding circuits (Hankir & Le Foll, 2025; Carvas et al., 2025).
How does cagrilintide achieve its long half-life?
A C18 fatty diacid moiety at the N-terminal lysine enables reversible albumin binding, protecting against renal clearance and enzymatic degradation to achieve a half-life of 159–195 hours (Kruse et al., 2021).
What distinguishes cagrilintide from newer AMYR-selective analogues?
Cagrilintide is non-selective across CTR and AMYRs, while NN1213 achieves ~29-fold AMY3R selectivity over CTR and eloralintide demonstrates an AMYR-preferring profile, potentially producing distinct biased signaling patterns (Dahl et al., 2024; Briere et al., 2025).
How do amylin and GLP-1 receptor agonists produce complementary effects?
Amylin receptors in the hindbrain and GLP-1 receptors in the hypothalamus enable parallel modulation of distinct satiety pathways. REDEFINE 1 showed 22.7% mean weight reduction with the combination at 68 weeks (Garvey et al., 2025).
References
All Oath Research peptides are tested for purity and identity. View our third-party lab results and certificates of analysis.
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
BPC-157 Benefits: Superior Gut Healing Peptide vs NSAIDs
Discover how BPC-157 benefits are setting a new standard for gut healing peptides, offering impressive potential for gastrointestinal recovery where traditional NSAIDs often fall short. If you’re curious about innovative, science-backed approaches to gut health, this might be the breakthrough you’ve been waiting for.